MESO · NasdaqGS
Mesoblast Limited
Biotechnology · Australia
- Market cap (USD)
- US$1.86B
- Trailing P/E
- —
- Forward P/E
- 31.41x
- Quarterly revenue growth
- 390.7%
- Trailing net margin
- -47.8%
- Indicated dividend yield
- —
Snapshot 2026-10-11 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Company background
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Company websiteFY2026
Go beyond the headline.
MESO Stock FY2026: Revenue Up 599%, And 46% Of The Price Is Unapproved
Published 2026-08-27
Comparable businesses
MESO peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | MESOMesoblast LimitedSnapshot 2026-10-11Financial period: 2026-06-30 |
|---|---|
| Market capMarket value, converted to USD | US$1.86B |
| Forward P/EProvider forward earnings estimate | 31.41x |
| EV / EBITDAEnterprise value / trailing EBITDA | — |
| Revenue growthLatest quarter vs prior-year quarter | 390.7% |
| Operating marginLatest reported quarter | -33.3% |
| Free cash flow yieldTrailing cash flow / market cap | -2.8% |
| Net debt / EBITDANet debt / trailing EBITDA | — |
| Debt / equityTotal debt / positive book equity | 0.22x |
| Trailing P/ETrailing twelve-month earnings | — |
| Price / bookPrice / positive book equity per share | 3.26x |
| EV / salesEnterprise value / trailing revenue | 15.66x |
| Earnings growthLatest quarter vs prior-year quarter | — |
| Gross marginTrailing twelve months | 80.0% |
| Net marginTrailing twelve months | -47.8% |
| Return on equityProvider trailing return; positive equity only | -9.9% |
| Free cash flow marginTrailing free cash flow / revenue | -43.2% |
| Dividend yieldIndicated annual dividend / price | — |
| Earnings payoutProvider trailing dividend payout | 0.0% |
| Current ratioCurrent assets / current liabilities | 2.44x |
| BetaProvider historical market sensitivity | 0.86 |
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for MESO
FY20262026-08-27
MESO Stock FY2026: Revenue Up 599%, And 46% Of The Price Is Unapproved
Presentation · 2026-08-27 · YouTube